Q1 Earnings Estimate for Immunocore Issued By HC Wainwright

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) – Stock analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for Immunocore in a research note issued to investors on Monday, April 20th. HC Wainwright analyst P. Trucchio expects that the company will post earnings per share of $0.05 for the quarter. HC Wainwright currently has a “Buy” rating and a $100.00 target price on the stock. The consensus estimate for Immunocore’s current full-year earnings is ($0.97) per share. HC Wainwright also issued estimates for Immunocore’s Q2 2027 earnings at $0.16 EPS, Q3 2027 earnings at $0.26 EPS and Q4 2027 earnings at $0.37 EPS.

Several other research firms have also recently issued reports on IMCR. Needham & Company LLC raised their price objective on Immunocore from $71.00 to $75.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Wall Street Zen cut Immunocore from a “buy” rating to a “hold” rating in a report on Saturday, January 31st. Mizuho set a $38.00 price objective on Immunocore in a report on Thursday, February 19th. UBS Group set a $55.00 price objective on Immunocore and gave the stock a “buy” rating in a report on Wednesday, January 7th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Immunocore in a report on Thursday, January 22nd. Six analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $60.89.

Immunocore Price Performance

IMCR stock opened at $29.98 on Wednesday. Immunocore has a 52-week low of $27.44 and a 52-week high of $40.71. The stock’s fifty day simple moving average is $31.51 and its 200-day simple moving average is $33.59. The company has a quick ratio of 4.01, a current ratio of 4.04 and a debt-to-equity ratio of 1.03. The stock has a market capitalization of $1.52 billion, a price-to-earnings ratio of -42.83 and a beta of 0.83.

Immunocore (NASDAQ:IMCR) last posted its quarterly earnings data on Saturday, February 14th. The company reported ($0.60) earnings per share (EPS) for the quarter. Immunocore had a negative return on equity of 9.20% and a negative net margin of 8.88%.The business had revenue of $104.48 million for the quarter.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. GAMMA Investing LLC raised its position in shares of Immunocore by 51.6% in the 3rd quarter. GAMMA Investing LLC now owns 914 shares of the company’s stock worth $33,000 after buying an additional 311 shares during the period. Harbour Investments Inc. raised its position in Immunocore by 60.2% in the fourth quarter. Harbour Investments Inc. now owns 1,033 shares of the company’s stock valued at $36,000 after purchasing an additional 388 shares during the period. DNB Asset Management AS raised its position in Immunocore by 6.4% in the third quarter. DNB Asset Management AS now owns 8,116 shares of the company’s stock valued at $295,000 after purchasing an additional 488 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in Immunocore by 37.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,120 shares of the company’s stock valued at $74,000 after purchasing an additional 572 shares during the period. Finally, R Squared Ltd raised its position in Immunocore by 7.4% in the fourth quarter. R Squared Ltd now owns 8,849 shares of the company’s stock valued at $307,000 after purchasing an additional 606 shares during the period. 84.50% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, insider David M. Berman sold 5,965 shares of the stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $32.35, for a total value of $192,967.75. Following the transaction, the insider directly owned 5,859 shares of the company’s stock, valued at approximately $189,538.65. This trade represents a 50.45% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Leger Tina Amber St sold 1,000 shares of the stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $32.35, for a total value of $32,350.00. Following the completion of the transaction, the insider directly owned 1,119 shares in the company, valued at $36,199.65. This trade represents a 47.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 19,137 shares of company stock valued at $619,082. 10.40% of the stock is currently owned by company insiders.

Immunocore Company Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.